121 related articles for article (PubMed ID: 24123836)
21. Multiple drug resistance in osteogenic sarcoma: INT0133 from the Children's Oncology Group.
Schwartz CL; Gorlick R; Teot L; Krailo M; Chen Z; Goorin A; Grier HE; Bernstein ML; Meyers P;
J Clin Oncol; 2007 May; 25(15):2057-62. PubMed ID: 17513810
[TBL] [Abstract][Full Text] [Related]
22. Predictive potential of ABCB1, ABCC3, and GSTP1 gene polymorphisms on osteosarcoma survival after chemotherapy.
Liu S; Yi Z; Ling M; Shi J; Qiu Y; Yang S
Tumour Biol; 2014 Oct; 35(10):9897-904. PubMed ID: 24996541
[TBL] [Abstract][Full Text] [Related]
23. Endothelin-1 promotes osteosarcoma cell invasion and survival against cisplatin-induced apoptosis.
Zhao Y; Liao Q; Zhu Y; Long H
Clin Orthop Relat Res; 2011 Nov; 469(11):3190-9. PubMed ID: 21656314
[TBL] [Abstract][Full Text] [Related]
24. Neoadjuvant chemotherapy for radioinduced osteosarcoma of the extremity: The Rizzoli experience in 20 cases.
Bacci G; Longhi A; Forni C; Fabbri N; Briccoli A; Barbieri E; Mercuri M; Balladelli A; Ferrari S; Picci P
Int J Radiat Oncol Biol Phys; 2007 Feb; 67(2):505-11. PubMed ID: 17118571
[TBL] [Abstract][Full Text] [Related]
25. Methotrexate in pediatric osteosarcoma: response and toxicity in relation to genetic polymorphisms and dihydrofolate reductase and reduced folate carrier 1 expression.
Patiño-García A; Zalacaín M; Marrodán L; San-Julián M; Sierrasesúmaga L
J Pediatr; 2009 May; 154(5):688-93. PubMed ID: 19159907
[TBL] [Abstract][Full Text] [Related]
26. Prognostic significance of early lymphocyte recovery in pediatric osteosarcoma.
Moore C; Eslin D; Levy A; Roberson J; Giusti V; Sutphin R
Pediatr Blood Cancer; 2010 Dec; 55(6):1096-102. PubMed ID: 20734401
[TBL] [Abstract][Full Text] [Related]
27. Calpain-6 is an endothelin-1 signaling dependent protective factor in chemoresistant osteosarcoma.
Marion A; Dieudonné FX; Patiño-Garcia A; Lecanda F; Marie PJ; Modrowski D
Int J Cancer; 2012 Jun; 130(11):2514-25. PubMed ID: 21681744
[TBL] [Abstract][Full Text] [Related]
28. Examination of the cutoff value of postchemotherapy increase in tumor volume as a predictor of subsequent oncologic events in stage IIB osteosarcoma.
Jeon DG; Kong CB; Cho WH; Song WS; Cho SH; Choi SW; Lee SY
J Surg Oncol; 2014 Mar; 109(3):275-9. PubMed ID: 24243222
[TBL] [Abstract][Full Text] [Related]
29. Germline genetic polymorphisms may influence chemotherapy response and disease outcome in osteosarcoma: a pilot study.
Windsor RE; Strauss SJ; Kallis C; Wood NE; Whelan JS
Cancer; 2012 Apr; 118(7):1856-67. PubMed ID: 21887680
[TBL] [Abstract][Full Text] [Related]
30. Neoadjuvant chemotherapy with methotrexate, cisplatin, and doxorubicin with or without ifosfamide in nonmetastatic osteosarcoma of the extremity: an Italian sarcoma group trial ISG/OS-1.
Ferrari S; Ruggieri P; Cefalo G; Tamburini A; Capanna R; Fagioli F; Comandone A; Bertulli R; Bisogno G; Palmerini E; Alberghini M; Parafioriti A; Linari A; Picci P; Bacci G
J Clin Oncol; 2012 Jun; 30(17):2112-8. PubMed ID: 22564997
[TBL] [Abstract][Full Text] [Related]
31. An expression signature classifies chemotherapy-resistant pediatric osteosarcoma.
Mintz MB; Sowers R; Brown KM; Hilmer SC; Mazza B; Huvos AG; Meyers PA; Lafleur B; McDonough WS; Henry MM; Ramsey KE; Antonescu CR; Chen W; Healey JH; Daluski A; Berens ME; Macdonald TJ; Gorlick R; Stephan DA
Cancer Res; 2005 Mar; 65(5):1748-54. PubMed ID: 15753370
[TBL] [Abstract][Full Text] [Related]
32. Can cure in patients with osteosarcoma be achieved exclusively with chemotherapy and abrogation of surgery?
Jaffe N; Carrasco H; Raymond K; Ayala A; Eftekhari F
Cancer; 2002 Nov; 95(10):2202-10. PubMed ID: 12412175
[TBL] [Abstract][Full Text] [Related]
33. The impact of catechol-O-methyltransferase SNPs and haplotypes on treatment response phenotypes in major depressive disorder: a case-control association study.
Kocabas NA; Faghel C; Barreto M; Kasper S; Linotte S; Mendlewicz J; Noro M; Oswald P; Souery D; Zohar J; Massat I
Int Clin Psychopharmacol; 2010 Jul; 25(4):218-27. PubMed ID: 20531207
[TBL] [Abstract][Full Text] [Related]
34. Association of -308G/A and -238G/A polymorphisms of TNF-α and osteosarcoma risk.
Zhao Z; Tang X; Song K; Li X; Zhang Y
Int J Clin Exp Pathol; 2015; 8(4):4177-81. PubMed ID: 26097610
[TBL] [Abstract][Full Text] [Related]
35. CD86 + 1057G/A polymorphism and susceptibility to osteosarcoma.
Wang W; Song H; Liu J; Song B; Cao X
DNA Cell Biol; 2011 Nov; 30(11):925-9. PubMed ID: 21563968
[TBL] [Abstract][Full Text] [Related]
36. The association between endothelin-1 gene polymorphisms and susceptibility to vitiligo in a Korean population.
Kim HJ; Choi CP; Uhm YK; Kim YI; Lee JW; Yoon SH; Chung JH; Lee MH
Exp Dermatol; 2007 Jul; 16(7):561-6. PubMed ID: 17576235
[TBL] [Abstract][Full Text] [Related]
37. [The prognostic significance of tumor volume in osteosarcoma with neoadjuvant chemotherapy].
Rehan N; Bieling P; Winkler P; Helmke K; Maas R; Baldini N; Heise U; Fuchs N; Winkler K
Klin Padiatr; 1993; 205(4):200-9. PubMed ID: 8377444
[TBL] [Abstract][Full Text] [Related]
38. Metastatic osteosarcoma at diagnosis: prognostic factors and long-term outcome--the French pediatric experience.
Mialou V; Philip T; Kalifa C; Perol D; Gentet JC; Marec-Berard P; Pacquement H; Chastagner P; Defaschelles AS; Hartmann O
Cancer; 2005 Sep; 104(5):1100-9. PubMed ID: 16015627
[TBL] [Abstract][Full Text] [Related]
39. Clinical analysis of Chinese limb osteosarcoma patients treated by two combinations of methotrexate, cisplatin, doxorubicin and ifosfamide.
Lin F; Wang Q; Yu W; Tang L; Zheng S; Sun Y; Shen Z; Yao Y; Dong Y
Asia Pac J Clin Oncol; 2011 Sep; 7(3):270-5. PubMed ID: 21884438
[TBL] [Abstract][Full Text] [Related]
40. Singe nucleotide polymorphisms in osteosarcoma: Pathogenic effect and prognostic significance.
Asnafi AA; Behzad MM; Ghanavat M; Shahjahani M; Saki N
Exp Mol Pathol; 2019 Feb; 106():63-77. PubMed ID: 30528563
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
